On May 8, 2025, the Court of Appeals for the Third Circuit affirmed the district court’s dismissal of AstraZeneca’s challenges to the Inflation Reduction Act’s Drug Price Negotiation Program and CMS’s Guidance implementing...more
5/16/2025
/ Administrative Procedure Act ,
Appeals ,
Article III ,
AstraZeneca ,
Centers for Medicare & Medicaid Services (CMS) ,
Constitutional Challenges ,
Drug Pricing ,
Inflation Reduction Act (IRA) ,
Judicial Review ,
Patents ,
Pharmaceutical Industry ,
Prescription Drugs ,
Standing
Today, the district court for the District of Delaware (Judge Connolly) granted the government’s motion for summary judgment on all claims brought by AstraZeneca in its Complaint challenging the Drug Price Negotiation Program...more
3/4/2024
/ Abbreviated New Drug Application (ANDA) ,
Administrative Procedure Act ,
AstraZeneca ,
Biosimilars ,
Centers for Medicare & Medicaid Services (CMS) ,
Drug Pricing ,
Due Process ,
Generic Drugs ,
Inflation Reduction Act (IRA) ,
Lack of Jurisdiction ,
Medicare ,
Pharmaceutical Industry ,
Prescription Drugs ,
Summary Judgment
Today, the district court for the Western District of Texas granted the government’s motion to dismiss the lawsuit brought by PhRMA and other organizations challenging the Drug Price Negotiation Program of the Inflation...more
2/13/2024
/ AstraZeneca ,
Boehringer ,
Bristol-Myers Squibb ,
Centers for Medicare & Medicaid Services (CMS) ,
Chamber of Commerce ,
Department of Health and Human Services (HHS) ,
Dismissals ,
Drug Pricing ,
Inflation Reduction Act (IRA) ,
Janssen Pharmaceuticals ,
Medicare ,
Medicare Act ,
Merck ,
Novartis ,
Novo Nordisk ,
Pharmaceutical Industry ,
PHRMA ,
Prescription Drugs ,
Secretary of HHS